Navigation Links
Src Inhibitors in Breast Cancer Therapy

Estrogen, which binds estrogen receptor alpha (ER-alpha), is a risk factor for breast cancer development. However, one-third of new breast cancers lack detectable ER-alpha .

These ER-alphanegative cancers are more aggressive and have a worse prognosis than do ER-alphapositive breast cancers, and have been thought to be estrogen independent.

In a study appearing online on July 12 in advance of publication in the August print issue of the Journal of Clinical Investigation, Joyce Slingerland and colleagues from the University of Miami shed further light on the mechanisms regulating ER-alpha expression levels during breast cancer.

In their study of 250 primary breast cancers, the authors found that ER mRNA levels overlap considerably between ER-alphapositive and ER-alphanegative breast cancers.

This lack of correlation between ER-alpha mRNA and protein levels pointed to the existence of important post-transcriptional control of ER-alpha expression.

They found that ER-alphanegative primary breast cancers and cell lines showed increased levels and/or activity of the protein Src, which cooperates with estrogen to activate ER-alpha breakdown via proteolysis.

In line with this finding, Src inhibition was shown to impair estrogen-stimulated ER-alpha proteolysis. The data raise the possibility that for at least a subset of ER-alphanegative breast cancers, Src may stimulate estrogen-dependent ER-alpha degradation, resulting in a lack of ER-alpha detection, and more aggressive tumor growth.

The authors conclude that their study provides a rationale for the use of Src inhibitors in breast cancer therapy.

AUTHOR CONTACT: Joyce M. Slingerland University of Miami Miller School of Medicine, Miami, Florida, USA. Phone : (305) 243-7265; Fax: (305) 243-4787; E-mail: jslingerland@med.miami.edu


'"/>




Page: 1

Related medicine news :

1. Aromatase Inhibitors drug Femara after Tamoxifen therapy protects from breast cancer recurrence
2. LipB Protein Inhibitors Help To Fight Against TB
3. Aromatase Inhibitors Better Than Tamoxifen For Treating Receptor-Positive Early Breast Cancer
4. ACE Inhibitors For Vascular Disease Patients
5. Green Tea and COX-2 Inhibitors Combine to Slow Growth of Prostate Cancer
6. Consensus on "Combination Therapy" for Breast Cancer
7. Breast cancer treatment to be determined by gene test
8. Breast Feeding prevents obesity later on in life
9. Breast milk is essential
10. Breast Cancer Surgery Causes Psychological problems
11. Breast cancer evidence
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Src Inhibitors Breast Cancer Therapy

(Date:12/5/2009)--In Youngest Babies, This Type of Blood Cancer Is Most Challenging-- ,, PHILADELPHIA and NEW ORLEANS, Dec. 5 Pediatric oncologists have identified specific genes, dubbed partner genes, that fuse w
(Date:12/5/2009)Research debunks the ,something,s wrong with being single, myth , , SATURDAY, Dec. 5 (HealthDay News) -- Pity the poor single people who pass their 40th birthday without ever tying the knot, s
(Date:12/5/2009)The MAMA campaign is a collaborative effort by the National Association of Certified Professional Midwives (NACPM), Midwives Alliance of North America (MANA), Citizens for Midwifery (CfM), Internation
(Date:12/4/2009)NEW YORK, Dec. 4 Care Investment Trust Inc. (NYSE: CRE ) ("Care" or the "Company") today announced that its Board of Directors has declared a dividend of $0.17 per share of common stock. The div
(Date:12/4/2009)PEMBROKE, Bermuda, Dec. 4 Allied World Assurance,Company Holdings, Ltd (NYSE: AWH ) today announced that Scott Carmilani,President and Chief Executive Officer, and Jack Sennott, Executive Vice,Pres
Breaking Medicine News(10 mins):Health News:New Gene Findings Will Help Guide Treatment in Infant Leukemia 2Health News:New Gene Findings Will Help Guide Treatment in Infant Leukemia 3Health News:New Gene Findings Will Help Guide Treatment in Infant Leukemia 4Health News:Never Married, Over 40, Well-Adjusted 2Health News:Never Married, Over 40, Well-Adjusted 3Health News:AquaNatal Birth Center Gives Away a Waterbirth Package to Celebrate the Successful MAMA Campaign 2Health News:AquaNatal Birth Center Gives Away a Waterbirth Package to Celebrate the Successful MAMA Campaign 3Health News:AquaNatal Birth Center Gives Away a Waterbirth Package to Celebrate the Successful MAMA Campaign 4Health News:Care Investment Trust Inc. Declares Quarterly Dividend of $0.17 Per Share 2Health News:Allied World to Present at the 2009 Goldman Sachs U.S. Financial Services Conference 2
...oposed by the Jharkhand government to donate nearl... the potential of Ayurveda.// The yoga guru has al...re and marketing of Ayurvedic medicine preparation...ek when he arrives here for a yoga camp at the inv...
...und through an animal study that Aspartame can cau...drinking four to five 20-ounce bottles of diet sod...//cause of cancers. The study would be publishe...ding 1,900 rats with artificial sweetener in feed ...
...titute of Trauma (MIOT) deserves to be called the ...mally invasive surgery (MIS) for all kinds of surg...ra that provides 40 fold magnification of a speci..., and joint replacements are all done using the wo...
...udit time and things are coming under the microsco...t the exchequer a whopping sum and while they stru...ton were paying up for frivolous operations like a...nses with thousands of dubious expenditures in 200...
...to manage the potential shortage of bird flu vacci... the anti-flu preparation, would soon be initiated... Roche Ltd. // Request by the Ministry of Health, ... two years. The Swiss based F. Hoffmann-La Roche L...
... John Howard has allocated $1.1 billion in health ... mental health groups. // Mr. Howard said that... are not aware off and hence the best thing is to ... illness is still considered as a big problem his ...
Other Medicine News:Health News:Any Form Of Minimally Invasive Surgery- Name It & They Do It! 2Health News:Misplaced Priorities in Medicaid Dispensation 2
(Date:12/4/2009)ANNAPOLIS, Md., Dec. 4 PharmAthene, Inc. (NYSE Amex: PIP ), a biodefense company developing medical countermeasures against biological and chemical threats, announced today the presentation of new d
(Date:12/4/2009)ANNAPOLIS, Md., Dec. 4 PharmAthene, Inc. (NYSE Amex: PIP ), a biodefense company developing medical countermeasures against biological and chemical threats, announced today that the Company is prese
(Date:12/4/2009)MORRISTOWN, N.J., Dec. 4 Watson Pharmaceuticals, Inc. (NYSE: WPI ), a leading global specialty pharmaceutical company, today confirmed that its subsidiary, Watson Laboratories, Inc.-Florida, filed
Breaking Medicine Technology:PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop 2PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop 3PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop 4PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop 5PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 2PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 3PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 4PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 5PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 6Watson Files FDA Application for Generic Rozerem(R) 2Watson Files FDA Application for Generic Rozerem(R) 3SHRM Testifies before Senate on H1N1 and Need for Flexible Paid Leave Policies 61068 1SHRM Testifies before Senate on H1N1 and Need for Flexible Paid Leave Policies 61068 2SHRM Testifies before Senate on H1N1 and Need for Flexible Paid Leave Policies 61068 3Reportlinker Adds Ophthalmology and Optometry Macular Degeneration 61065 1Reportlinker Adds Ophthalmology and Optometry Macular Degeneration 61065 2Cardium Reports on Third Quarter 2009 Financial Results and Recent Developments 14776 1Cardium Reports on Third Quarter 2009 Financial Results and Recent Developments 14776 2Cardium Reports on Third Quarter 2009 Financial Results and Recent Developments 14776 3Cardium Reports on Third Quarter 2009 Financial Results and Recent Developments 14776 4Cardium Reports on Third Quarter 2009 Financial Results and Recent Developments 14776 5Cardium Reports on Third Quarter 2009 Financial Results and Recent Developments 14776 6Cardium Reports on Third Quarter 2009 Financial Results and Recent Developments 14776 7Cardium Reports on Third Quarter 2009 Financial Results and Recent Developments 14776 8Cardium Reports on Third Quarter 2009 Financial Results and Recent Developments 14776 9Cardium Reports on Third Quarter 2009 Financial Results and Recent Developments 14776 10Cardium Reports on Third Quarter 2009 Financial Results and Recent Developments 14776 11Cardium Reports on Third Quarter 2009 Financial Results and Recent Developments 14776 12Cardium Reports on Third Quarter 2009 Financial Results and Recent Developments 14776 13Cardium Reports on Third Quarter 2009 Financial Results and Recent Developments 14776 14Cardium Reports on Third Quarter 2009 Financial Results and Recent Developments 14776 15
...arget from Lexicon,s Genetic,Research -, THE WOODL...--,Lexicon Pharmaceuticals, Inc. today reported re... antibodies directed to a,potential new target, an... triglycerides and cholesterol. Research suggests ... may have therapeutic,application in the treatment...
... 3, 2007 - Cytos Biotechnology,AG (SWX:CYTN) annou...003-QbG10 in atopic dermatitis. CYT003-QbG10 is an...development for,the treatment of allergic diseases...bility and exploratory efficacy of the product,can...is. The study,was designed as a placebo-controlled...
Other Medicine Technology:Lexicon Develops Antibodies That Lower Triglycerides and,Cholesterol as Potential New Therapy for Heart Disease 2Lexicon Develops Antibodies That Lower Triglycerides and,Cholesterol as Potential New Therapy for Heart Disease 3Lexicon Develops Antibodies That Lower Triglycerides and,Cholesterol as Potential New Therapy for Heart Disease 4Lexicon Develops Antibodies That Lower Triglycerides and,Cholesterol as Potential New Therapy for Heart Disease 5Cytos Biotechnology Reports Results from Phase IIa Study with,CYT003-QbG10 in Patients Suffering from Atopic Dermatitis 2Cytos Biotechnology Reports Results from Phase IIa Study with,CYT003-QbG10 in Patients Suffering from Atopic Dermatitis 3Cytos Biotechnology Reports Results from Phase IIa Study with,CYT003-QbG10 in Patients Suffering from Atopic Dermatitis 4Cytos Biotechnology Reports Results from Phase IIa Study with,CYT003-QbG10 in Patients Suffering from Atopic Dermatitis 5
...icare's Prep Pads offer convenience, low cost, eas...applications. Each package is terminally sterilize...tient. Sterile Skin Protectant Prep Pads prepare t...dage. When dry, it leaves a thin film on the skin'...
IV Prep Swab Sticks
Triad Plus BZK Swabsticks
...ad Plus PVP-I Prep Swabsticks are saturated with a...to 1% available iodine. Povidone Iodine is vir...branes. It is also non-staining to the skin or nat...s on contact; they are sturdy tools for removing s...
Medicine Products: